Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Christine Phillips to Male

This is a "connection" page, showing publications Christine Phillips has written about Male.

 
Connection Strength
 
 
 
0.143
 
  1. Breese EH, Krupski C, Nelson AS, Perentesis JP, Phillips CL. Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2021 05 01; 43(4):152-154.
    View in: PubMed
    Score: 0.032
  2. Rubinstein JD, Nelson AS, Krupski C, O'Brien W, Taylor JM, Badgett TC, Huang M, Davies SM, Phillips CL. Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities. Pediatr Blood Cancer. 2020 04; 67(4):e28199.
    View in: PubMed
    Score: 0.029
  3. Dixon SB, Lane A, O'Brien MM, Burns KC, Mangino JL, Breese EH, Absalon MJ, Perentesis JP, Phillips CL. Viral surveillance using PCR during treatment of AML and ALL. Pediatr Blood Cancer. 2018 Jan; 65(1).
    View in: PubMed
    Score: 0.025
  4. Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol. 2013 May; 161(3):406-10.
    View in: PubMed
    Score: 0.018
  5. Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug; 55(2):248-53.
    View in: PubMed
    Score: 0.015
  6. Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood. 2021 11 25; 138(21):2138-2142.
    View in: PubMed
    Score: 0.008
  7. Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, Davies SM, Phillips CL, Driscoll TA, Bader P, Schlis K, Wood PA, Mody R, Yi L, Leung M, Eldjerou LK, June CH, Maude SL. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.008
  8. Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv. 2019 07 09; 3(13):1926-1929.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)